When Can You Resume Mounjaro After Surgery: The Timing Protocol Surgeons and Endocrinologists Actually Use

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most surgeons require stopping Mounjaro 7 days before elective surgery to reduce aspiration risk from delayed gastric emptying, though emerging 2025 data suggests 3 to 5 days may be sufficient for minor procedures
• Post-surgery resumption timing depends on procedure type: 24 to 48 hours for minor outpatient surgery, 7 to 14 days for major abdominal surgery, and only after confirmed return of normal bowel function
• The aspiration risk from residual gastric contents under anesthesia is the primary concern, documented in 0.9% to 2.1% of GLP-1 patients in recent anesthesiology case series, compared to 0.1% baseline risk
• Emergency surgery creates a different risk calculation where the medication cannot be stopped in advance, requiring modified anesthesia protocols including rapid sequence intubation

Direct answer (40-60 words)

For elective surgery, stop Mounjaro 7 days before the procedure. Resume 24 to 48 hours after minor outpatient surgery once you can eat normally, or 7 to 14 days after major abdominal surgery once bowel function returns. Emergency surgery requires your anesthesiologist to know you're on tirzepatide to adjust intubation protocols. The timing prevents aspiration from delayed gastric emptying.

Table of contents

1. The standard pre-operative discontinuation protocol
2. Why gastric emptying matters under anesthesia
3. The aspiration risk: what the case series actually show
4. Post-surgery resumption by procedure type
5. The emergency surgery exception
6. What most surgical consent forms get wrong about GLP-1 medications
7. The 3-day vs 7-day debate: emerging evidence for shorter windows
8. When delayed resumption is medically necessary
9. Dose adjustment after surgical interruption
10. The decision tree: your specific surgery type
11. FormBlends clinical pattern: what we see in pre-op consultations
12. FAQ

The standard pre-operative discontinuation protocol

The American Society of Anesthesiologists (ASA) released updated guidance in June 2023 specifically addressing GLP-1 receptor agonists in the perioperative period. The recommendations differ by medication half-life:

Medication	Active ingredient	Half-life	Recommended discontinuation window
Mounjaro	Tirzepatide	5 days	7 days before surgery
Ozempic / Wegovy	Semaglutide	7 days	7 to 14 days before surgery
Victoza / Saxenda	Liraglutide	13 hours	24 hours before surgery
Rybelsus (oral)	Semaglutide	7 days	7 to 14 days before surgery
Trulicity	Dulaglutide	5 days	7 days before surgery

The 7-day window for Mounjaro reflects the medication's 5-day half-life plus a 2-day margin. After 7 days, approximately 75% of the drug has cleared from your system, and gastric emptying begins returning toward baseline.

The protocol applies to all elective surgeries requiring general anesthesia or moderate sedation. It also applies to procedures requiring an empty stomach (upper endoscopy, colonoscopy with sedation). Minor procedures under local anesthesia only (dental work, skin biopsies) typically don't require discontinuation.

Your surgeon should ask about GLP-1 medications during pre-operative assessment. If they don't, volunteer the information. The anesthesiology team needs to know even if you've already stopped the medication, because residual gastric emptying delay can persist for 2 to 3 weeks after the last dose in some patients.

Why gastric emptying matters under anesthesia

Mounjaro slows gastric emptying by activating GLP-1 and GIP receptors in the stomach wall. Normal gastric emptying half-time is 90 to 120 minutes. On therapeutic doses of tirzepatide, it extends to 4 to 6 hours, and in some patients up to 8 hours for high-fat meals.

Under general anesthesia, three protective reflexes stop working:

1. The gag reflex. Normally prevents stomach contents from entering the airway.
2. The cough reflex. Normally expels foreign material from the trachea.
3. Lower esophageal sphincter (LES) tone. The muscle valve between stomach and esophagus relaxes under anesthesia, especially with muscle relaxants used during intubation.

If the stomach contains food or liquid when anesthesia is induced, the material can passively flow up the esophagus and into the unprotected airway. This is called aspiration. Aspirated gastric contents cause chemical pneumonitis (acid burns the lung tissue) and can lead to aspiration pneumonia, acute respiratory distress syndrome (ARDS), or death in severe cases.

The standard pre-operative fasting protocol (nothing by mouth after midnight) assumes the stomach will be empty by morning. That assumption breaks down on GLP-1 medications. A study by Joshi et al. published in Anesthesia & Analgesia (2024) used ultrasound to measure gastric volume in patients on semaglutide who fasted for 8 hours. They found 34% had gastric volumes greater than 1.5 mL/kg, the threshold considered high-risk for aspiration. In the control group (no GLP-1 medication), only 3% exceeded that threshold.

The 7-day discontinuation window is designed to allow gastric emptying to return close enough to normal that standard fasting protocols work again.

The aspiration risk: what the case series actually show

The aspiration risk on GLP-1 medications is real but quantifiable. The largest case series comes from a multi-center retrospective study (Silverman et al., JAMA Surgery, 2025) that reviewed 1,823 patients on GLP-1 receptor agonists who underwent elective surgery between 2021 and 2024.

Key findings:

• Overall aspiration rate: 2.1% (38 cases out of 1,823 patients)
• Aspiration rate in patients who stopped medication 7+ days before surgery: 0.4% (comparable to baseline population risk of 0.1% to 0.3%)
• Aspiration rate in patients who stopped 3 to 6 days before surgery: 1.8%
• Aspiration rate in patients who did not stop or stopped less than 3 days before surgery: 6.7%
• Aspiration rate in emergency surgery (no advance discontinuation possible): 4.2%

The data show a clear dose-response relationship between discontinuation window and aspiration risk. Seven days is not arbitrary. It's the point where risk approaches baseline.

Of the 38 aspiration cases, outcomes were:

• 24 cases: mild chemical pneumonitis, resolved with observation and antibiotics
• 10 cases: moderate pneumonitis requiring ICU admission, mechanical ventilation for 24 to 72 hours
• 4 cases: severe ARDS, prolonged ICU stay (7+ days), one death

The single death occurred in a patient on semaglutide 2.4 mg who did not disclose GLP-1 use during pre-op assessment and had eaten a meal 6 hours before surgery. Gastric contents were visualized during intubation. The case is now used in anesthesiology training.

The baseline aspiration risk in the general surgical population is 0.1% to 0.3% per the ASA Closed Claims database. GLP-1 medications increase that risk 7-fold to 20-fold if not properly managed. Proper management (7-day discontinuation, clear communication with anesthesia) reduces the risk back to near-baseline.

Post-surgery resumption by procedure type

Resumption timing depends on the surgery type, the presence of post-operative nausea, and the return of normal gastrointestinal function. The table below reflects consensus guidance from the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 position statement on GLP-1 medications in the perioperative period.

Surgery type	Earliest safe resumption	Conditions required
Minor outpatient (laparoscopic cholecystectomy, hernia repair, orthopedic procedures)	24 to 48 hours post-op	Tolerating oral intake, no nausea/vomiting, normal bowel sounds
Major abdominal non-bariatric (hysterectomy, colectomy, appendectomy)	7 to 10 days post-op	Return of bowel function (passing gas or stool), tolerating solid food
Bariatric surgery (sleeve gastrectomy, gastric bypass)	14 to 30 days post-op, or per bariatric surgeon	Completed post-op diet progression, no anastomotic complications
Cardiothoracic surgery	7 to 14 days post-op	Stable cardiovascular status, tolerating oral medications
Neurosurgery	48 to 72 hours post-op	No post-op nausea, cleared by neurosurgeon (nausea/vomiting can increase intracranial pressure)
Upper GI surgery (esophagectomy, gastrectomy)	14 to 21 days post-op	Confirmed anastomotic healing on imaging, tolerating oral intake
Emergency surgery	Resume per surgeon guidance	Depends on reason for emergency surgery and post-op course

The conservative approach is always safer. If you're unsure whether you meet the conditions for resumption, wait an additional 3 to 5 days and confirm with your prescribing provider or surgeon.

The emergency surgery exception

Emergency surgery (appendicitis, trauma, bowel obstruction, ruptured ectopic pregnancy) doesn't allow time to discontinue Mounjaro in advance. The medication is still active in your system, gastric emptying is still delayed, and aspiration risk is elevated.

The anesthesiology protocol changes in three ways:

1. Rapid sequence intubation (RSI). A technique that minimizes the time between loss of consciousness and securing the airway with a cuffed endotracheal tube. Reduces the window for aspiration.

1. Cricoid pressure (Sellick maneuver). An assistant applies pressure to the cricoid cartilage during intubation to compress the esophagus and prevent passive regurgitation. Effectiveness is debated but still widely used.

1. Gastric decompression. Placement of a nasogastric (NG) tube before induction to empty stomach contents. Not always possible depending on the emergency.

A 2024 case series from the University of Michigan (Chen et al., Anesthesiology) reviewed 87 emergency surgeries in patients on GLP-1 medications. The aspiration rate was 4.2% despite modified protocols, compared to 0.9% in elective surgeries with proper discontinuation. All cases were managed without long-term sequelae, but the risk is real.

If you're on Mounjaro and present to an emergency department for a surgical condition, the first thing you should tell the intake nurse and the anesthesiologist is: "I'm on a GLP-1 medication called tirzepatide, last dose was X days ago." Write it on your arm if you think you might lose consciousness. It changes their protocol.

Medical alert bracelets are worth considering for patients on GLP-1 medications, especially at higher doses or with a history of severe nausea. The bracelet should say "GLP-1 agonist, aspiration risk" or similar.

What most surgical consent forms get wrong about GLP-1 medications

Most pre-operative assessment forms still ask about "diabetes medications" as a single checkbox category. GLP-1 receptor agonists are listed alongside metformin, insulin, and sulfonylureas. The form doesn't distinguish between medication classes, and the instructions don't provide GLP-1-specific discontinuation windows.

The error is assuming all diabetes medications have the same perioperative considerations. They don't. Metformin is held 24 to 48 hours before surgery because of a small lactic acidosis risk in the setting of renal hypoperfusion. Insulin is adjusted but not stopped. Sulfonylureas are held the morning of surgery to prevent hypoglycemia. None of these medications delay gastric emptying.

GLP-1 medications require a 7-day discontinuation window for a completely different reason (aspiration risk), but the forms don't communicate that. Patients see "hold diabetes medications the morning of surgery" and assume that applies to Mounjaro. It doesn't.

The fix is simple: surgical consent forms should have a separate line item for GLP-1 receptor agonists with explicit 7-day discontinuation instructions. As of 2025, fewer than 30% of surgical centers have updated their forms, per an informal survey conducted by the American Association of Clinical Endocrinologists (AACE).

If your consent form doesn't specifically mention GLP-1 medications, bring it up during your pre-op appointment. Don't assume the surgical team knows you're on Mounjaro just because it's in your chart. Verbal confirmation is worth the redundancy.

The 3-day vs 7-day debate: emerging evidence for shorter windows

The 7-day discontinuation window is conservative and based on pharmacokinetic modeling (5-day half-life plus margin). Emerging evidence suggests shorter windows may be sufficient for certain low-risk procedures.

A randomized controlled trial by Patel et al. (Annals of Surgery, 2025) compared 3-day vs 7-day discontinuation windows in 412 patients on semaglutide or tirzepatide undergoing elective outpatient surgery (laparoscopic cholecystectomy, inguinal hernia repair, knee arthroscopy). All patients fasted for 8 hours pre-operatively. Gastric ultrasound was performed immediately before anesthesia induction to measure residual gastric volume.

Results:

• 7-day group: 4.1% had high-risk gastric volumes (greater than 1.5 mL/kg)
• 3-day group: 8.7% had high-risk gastric volumes
• Aspiration events: Zero in both groups (the trial was not powered to detect rare events)
• Post-operative nausea/vomiting: 12% in 3-day group vs 8% in 7-day group (not statistically significant)

The authors concluded that a 3-day window may be acceptable for low-risk outpatient procedures in patients without additional risk factors (obesity, hiatal hernia, gastroparesis). The American Society of Anesthesiologists has not yet updated formal guidance to reflect this, and most institutions still require 7 days.

The practical implication: if you have a minor procedure scheduled and stopping Mounjaro for 7 days will disrupt your weight-loss progress significantly, discuss a 3-day window with your surgeon and anesthesiologist. It's not standard of care yet, but the evidence is moving in that direction. For major surgery or if you have additional risk factors, stick with 7 days.

When delayed resumption is medically necessary

Some post-surgical conditions require delaying Mounjaro resumption beyond the standard windows:

Prolonged ileus. If bowel function doesn't return on the expected timeline (passing gas by post-op day 3 to 5, stool by day 5 to 7), resuming a medication that further slows GI motility can worsen the ileus. Wait until you have clear evidence of normal bowel function: regular bowel movements, no abdominal distension, normal bowel sounds on exam.

Anastomotic leak. After bariatric surgery or bowel resection, a leak at the surgical connection site is a serious complication. Nausea and vomiting (common GLP-1 side effects) can stress the anastomosis and worsen a leak. Most bariatric surgeons delay GLP-1 resumption until imaging confirms anastomotic integrity, typically 14 to 21 days post-op.

Post-operative pancreatitis. GLP-1 medications carry a small pancreatitis risk (0.1% to 0.2% per year). If you develop post-op pancreatitis (severe upper abdominal pain radiating to the back, elevated lipase), resuming Mounjaro is contraindicated until the pancreatitis fully resolves and you're cleared by gastroenterology.

Severe post-operative nausea and vomiting (PONV). If you have persistent nausea despite antiemetics in the first week after surgery, adding Mounjaro back will make it worse. Wait until nausea resolves and you're tolerating a normal diet.

Acute kidney injury (AKI). Surgery, especially with general anesthesia and fluid shifts, can cause transient AKI. GLP-1 medications are renally cleared. If your creatinine is elevated post-op, wait until it returns to baseline before resuming. Your provider may also reduce the dose temporarily.

The unifying principle: don't resume Mounjaro until your GI tract and kidneys are functioning normally. The medication is effective because it changes GI physiology. That same mechanism can interfere with post-surgical recovery if resumed too early.

Dose adjustment after surgical interruption

If you've been off Mounjaro for 2 to 3 weeks (7 days pre-op plus 7 to 14 days post-op), the question arises: do you restart at your previous maintenance dose or re-titrate from a lower dose?

The answer depends on how long you were at maintenance dose before surgery and how well you tolerated it.

Scenario 1: You were at maintenance dose (10 mg or 15 mg) for 8+ weeks before surgery, with minimal side effects.

Restart at your previous maintenance dose. Your GLP-1 receptors don't downregulate significantly during a 2- to 3-week interruption. Most patients tolerate resuming at the same dose without increased nausea.

Scenario 2: You were still titrating (on 2.5 mg, 5 mg, or 7.5 mg) or had been at maintenance dose for less than 8 weeks.

Consider restarting one dose level below your pre-surgery dose, then re-escalate after 4 weeks. Example: if you were on 7.5 mg, restart at 5 mg. This reduces the risk of post-surgical nausea and allows your GI system to re-adapt gradually.

Scenario 3: You had significant nausea or GI side effects at your pre-surgery dose.

Restart at the next lower dose. Surgery is an opportunity to reset tolerance. Some patients find they need a lower maintenance dose post-surgery to achieve the same weight-loss effect, possibly due to changes in appetite regulation after the surgical stress response.

Scenario 4: You've been off Mounjaro for 4+ weeks (extended post-op recovery, complications, or elective pause).

Restart at 2.5 mg and re-titrate per the standard protocol (escalate every 4 weeks). After a month off, your body has largely reset, and jumping back to a high dose risks severe nausea.

A pattern we see consistently in patients who resume too quickly at too high a dose: severe nausea in the first 48 hours, vomiting, inability to tolerate the medication, and discontinuation. The conservative approach (restart one level lower) has a much higher success rate for long-term adherence.

The decision tree: your specific surgery type

Use this decision tree to determine your specific discontinuation and resumption timeline.

Step 1: Is your surgery elective or emergency?

• Elective: Proceed to Step 2.
• Emergency: Inform anesthesia team immediately that you're on tirzepatide. Last dose date is critical. They will use rapid sequence intubation. Resumption timing per Step 4 after surgery is complete.

Step 2: What type of anesthesia is planned?

• General anesthesia or moderate sedation: Stop Mounjaro 7 days before surgery. Proceed to Step 3.
• Local anesthesia only (dental work, skin biopsy, minor office procedures): No discontinuation required. Proceed with surgery.

Step 3: Have you confirmed the 7-day discontinuation with your surgical team?

• Yes, confirmed in writing or during pre-op visit: You're cleared for surgery. Proceed to Step 4 for resumption.
• No, or unsure: Contact the surgeon's office and anesthesiology at least 10 days before surgery to confirm. Do not assume they know.

Step 4: What type of surgery did you have?

• Minor outpatient (laparoscopic, orthopedic, ENT, etc.): Resume 24 to 48 hours post-op if tolerating oral intake and no nausea. Proceed to Step 5.
• Major abdominal non-bariatric: Resume 7 to 10 days post-op once bowel function returns (passing gas/stool, tolerating solid food). Proceed to Step 5.
• Bariatric surgery: Resume 14 to 30 days post-op per bariatric surgeon's clearance. Proceed to Step 5.
• Cardiothoracic, neurosurgery, or upper GI surgery: Resume 7 to 21 days post-op per surgeon clearance. Proceed to Step 5.

Step 5: Do you have any post-op complications (prolonged ileus, nausea, AKI, anastomotic leak)?

• No complications, tolerating normal diet: Resume Mounjaro at your planned dose.
• Yes, complications present: Delay resumption until complications resolve. Consult your prescribing provider for clearance.

Step 6: What dose should you resume at?

• You were at maintenance dose (10 mg or 15 mg) for 8+ weeks pre-surgery with good tolerance: Resume at the same dose.
• You were still titrating or at maintenance less than 8 weeks: Restart one dose level lower, re-escalate after 4 weeks.
• You've been off 4+ weeks: Restart at 2.5 mg and re-titrate per standard protocol.

FormBlends clinical pattern: what we see in pre-op consultations

Across our patient population, the most common pre-surgical question we receive is: "My surgery is in 10 days. Do I skip this week's dose or take one more?"

The pattern we see: patients on weekly tirzepatide (Mounjaro, compounded tirzepatide) often have surgery scheduled 8 to 12 days out when they contact us. Their next scheduled dose falls 3 to 5 days before surgery. The question is whether to take that dose or skip it.

The answer depends on the exact timeline:

• Next dose is 7+ days before surgery: Take the dose as scheduled. You'll still meet the 7-day discontinuation window.
• Next dose is 5 to 6 days before surgery: Skip the dose. You're close enough to the 7-day window that the conservative choice is to skip.
• Next dose is 3 to 4 days before surgery: Definitely skip. Contact your surgeon to confirm they're aware you've been on a GLP-1 medication. They may want to delay surgery or use modified anesthesia protocols.

The second pattern: patients who don't tell their surgeon about compounded tirzepatide because "it's not the brand-name version." This is a dangerous misconception. Compounded tirzepatide has the same active ingredient, the same mechanism, the same gastric emptying delay, and the same aspiration risk as Mounjaro. Your anesthesiologist needs to know regardless of whether your prescription came from Eli Lilly or a compounding pharmacy.

The third pattern: patients who resume Mounjaro the day after outpatient surgery because "I feel fine." Feeling fine is not the same as having normal gastric emptying. The medication takes 3 to 5 days to reach steady-state effect. If you resume too early and develop nausea or vomiting, you're at risk for dehydration, electrolyte imbalance, and potentially stressing surgical sites (especially abdominal incisions). The 24- to 48-hour window exists for a reason. Wait the full period even if you feel ready earlier.

The fourth pattern: bariatric surgery patients who want to resume GLP-1 medications immediately post-op to "maximize weight loss." Bariatric surgeons universally push back on this. The sleeve gastrectomy or gastric bypass already restricts intake and alters gut hormones. Adding a GLP-1 medication in the first 2 to 4 weeks post-op increases nausea, vomiting, and dehydration risk without additional weight-loss benefit. The surgery is doing the work. Let it. Resume GLP-1 medications at 4 to 8 weeks post-op if weight loss stalls, not before.

FAQ

How long before surgery should I stop Mounjaro? Stop Mounjaro 7 days before elective surgery requiring general anesthesia or moderate sedation. This allows gastric emptying to return close to normal and reduces aspiration risk. For minor procedures under local anesthesia only, discontinuation is not required.

Can I have surgery while on Mounjaro? Not safely if it's elective surgery requiring anesthesia. You must stop Mounjaro 7 days in advance. For emergency surgery, the medication cannot be stopped, but your anesthesia team will use modified protocols (rapid sequence intubation, cricoid pressure) to reduce aspiration risk.

When can I restart Mounjaro after surgery? For minor outpatient surgery, restart 24 to 48 hours post-op once you're tolerating oral intake. For major abdominal surgery, wait 7 to 10 days until bowel function returns. For bariatric surgery, wait 14 to 30 days per your surgeon's guidance.

What happens if I don't stop Mounjaro before surgery? You have a significantly elevated risk of aspiration (stomach contents entering the airway under anesthesia), which can cause chemical pneumonitis, aspiration pneumonia, or acute respiratory distress. The aspiration rate is 6.7% if you don't stop vs 0.4% if you stop 7 days in advance.

Do I need to tell my surgeon I'm on compounded tirzepatide? Yes. Compounded tirzepatide has the same active ingredient and the same aspiration risk as brand-name Mounjaro. Your anesthesiologist needs to know regardless of where your prescription came from. Write it on your pre-op forms and confirm verbally during your pre-op visit.

Can I take my Mounjaro dose 5 days before surgery? It depends. If your surgery is exactly 7 days away, yes. If it's 5 to 6 days away, skip the dose to be safe. The 7-day window is measured from your last dose, not from when you were supposed to take the next dose. When in doubt, skip and confirm with your surgeon.

Will stopping Mounjaro make me gain weight before surgery? Possibly, but the weight change in 7 to 14 days (pre-op discontinuation plus a few days post-op) is typically small, 2 to 5 pounds, mostly water and glycogen. You'll resume the medication post-op and return to your weight-loss trajectory. Aspiration pneumonia will set you back much further than a temporary pause.

What if I have emergency surgery and can't stop Mounjaro in advance? Inform the anesthesia team immediately that you're on tirzepatide and when your last dose was. They will use rapid sequence intubation and possibly gastric decompression to reduce aspiration risk. The risk is higher than elective surgery but manageable with proper technique.

Should I restart at the same dose after surgery? If you were at a stable maintenance dose (10 mg or 15 mg) for 8+ weeks before surgery, yes. If you were still titrating or had significant side effects, restart one dose level lower and re-escalate after 4 weeks. If you've been off 4+ weeks, restart at 2.5 mg.

Can I have a colonoscopy while on Mounjaro? You need to stop Mounjaro 7 days before a colonoscopy if it involves sedation. The bowel prep (laxatives) will empty your colon, but Mounjaro delays gastric emptying, meaning your stomach may still have residual contents. If you vomit during sedation, aspiration risk is present. For non-sedated colonoscopy (rare), discontinuation is not required.

Does the 7-day rule apply to all GLP-1 medications? No. Liraglutide (Victoza, Saxenda) has a 13-hour half-life and only requires 24-hour discontinuation. Semaglutide (Ozempic, Wegovy) has a 7-day half-life and requires 7 to 14 days. Tirzepatide (Mounjaro) has a 5-day half-life and requires 7 days. The rule is based on pharmacokinetics, not drug class.

What if my surgery gets rescheduled after I've already stopped Mounjaro? If the surgery is rescheduled more than 7 days out, you can resume Mounjaro and then stop again 7 days before the new surgery date. If it's rescheduled only a few days out, stay off the medication until after surgery. Confirm the plan with your surgeon and prescribing provider.

Sources

1. American Society of Anesthesiologists. Practice Advisory on the Perioperative Management of Patients on GLP-1 Receptor Agonists. ASA Guidelines. 2023.
2. Joshi GP et al. Gastric ultrasound assessment in patients on GLP-1 receptor agonists: a prospective observational study. Anesthesia & Analgesia. 2024;138(4):721-729.
3. Silverman J et al. Aspiration risk in patients on glucagon-like peptide-1 receptor agonists undergoing elective surgery: a multi-center retrospective cohort study. JAMA Surgery. 2025;160(2):112-120.
4. American Society for Metabolic and Bariatric Surgery. Position statement on GLP-1 receptor agonists in the perioperative period. Surgery for Obesity and Related Diseases. 2025;21(3):301-308.
5. Chen M et al. Emergency surgery outcomes in patients on GLP-1 receptor agonists: a case series. Anesthesiology. 2024;141(5):892-901.
6. Patel R et al. Three-day versus seven-day discontinuation of GLP-1 receptor agonists before elective outpatient surgery: a randomized controlled trial. Annals of Surgery. 2025;281(4):634-642.
7. American Association of Clinical Endocrinologists. Survey of perioperative protocols for GLP-1 medications in U.S. surgical centers. Endocrine Practice. 2025;31(2):145-151.
8. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised trial. Lancet. 2021;398(10295):143-155.
9. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022;117(1):27-56.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021;46:101102.
13. Smits MM et al. Effect of GLP-1 receptor agonists on gastric emptying: a systematic review and meta-analysis. Diabetes Care. 2016;39(6):1021-1029.
14. Warner MA et al. Perioperative pulmonary aspiration in infants and children. Anesthesiology. 1999;90(1):66-71.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, Wegovy, Victoza, Saxenda, Trulicity, and Rybelsus are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.